Bruker Co. (NASDAQ:BRKR) Stake Raised by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in Bruker Co. (NASDAQ:BRKR) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 890,189 shares of the medical research company’s stock after acquiring an additional 21,793 shares during the period. Janus Henderson Group PLC owned about 0.59% of Bruker worth $61,480,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BRKR. Tidal Investments LLC purchased a new stake in Bruker in the 1st quarter worth about $218,000. Cetera Investment Advisers raised its stake in shares of Bruker by 350.0% during the 1st quarter. Cetera Investment Advisers now owns 33,131 shares of the medical research company’s stock worth $3,112,000 after purchasing an additional 25,768 shares in the last quarter. Cetera Advisors LLC purchased a new stake in shares of Bruker during the 1st quarter worth about $693,000. CWM LLC raised its stake in shares of Bruker by 165.4% during the 2nd quarter. CWM LLC now owns 4,777 shares of the medical research company’s stock worth $305,000 after purchasing an additional 2,977 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Bruker by 2,125.7% during the 2nd quarter. SG Americas Securities LLC now owns 27,465 shares of the medical research company’s stock worth $1,753,000 after purchasing an additional 26,231 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Performance

BRKR opened at $58.48 on Friday. The firm has a market capitalization of $8.87 billion, a P/E ratio of 28.12, a price-to-earnings-growth ratio of 3.86 and a beta of 1.18. The stock’s 50 day moving average price is $59.84 and its two-hundred day moving average price is $63.60. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter in the prior year, the business posted $0.74 EPS. Bruker’s revenue was up 16.4% compared to the same quarter last year. On average, equities analysts forecast that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Bruker’s dividend payout ratio is currently 9.62%.

Insiders Place Their Bets

In other news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction on Monday, November 18th. The stock was bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 28.30% of the company’s stock.

Wall Street Analyst Weigh In

BRKR has been the subject of a number of recent research reports. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Barclays cut their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a report on Thursday. Finally, TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.